Drug Channels
APRIL 26, 2024
Kevin asks: What if there were no barriers across the therapy access and reimbursement process? Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Today’s guest post comes from Kevin Kettler, President of CoverMyMeds. Read on for Kevin’s insights. All rights reserved.
Drug Target Review
JUNE 19, 2024
The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
JULY 7, 2023
Sahil discusses how manufacturers can balance patients’ access to therapy with gross-to-net (GTN) goals. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc. Read on for Sahil’s insights.
Drug Channels
NOVEMBER 11, 2022
Today’s guest post comes from Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. Lung-I discusses advancements in cell and gene therapy and explains how to tackle the challenges facing manufacturers, providers, and patients. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc.
Drug Channels
OCTOBER 28, 2022
Brooks introduces us to CareMetx’s specialty therapy warranty, a specialty patient outcome-based contract model. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.
Drug Channels
MARCH 28, 2024
Bill discusses specialty therapy access barriers, including payer utilization management techniques and “no coverage” policies. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Today’s guest post comes from Bill Dupere, SVP of Product Development & Partnerships at Mercalis.
Drug Channels
MAY 9, 2024
Today’s guest post comes from Hannah Baxter, Associate Partner at The Dedham Group; Jen Klarer, Partner, Head of Cell & Gene Therapy at The Dedham Group; and Carolyn Zele, Advisor, Solution Consulting at MMIT. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Expert insights. Personalized for you.
96 
Let's personalize your content